Literature DB >> 21839028

A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Giovanni Di Minno1, Antonio Coppola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839028      PMCID： PMC3159912          DOI： 10.2450/2011.004S

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  49 in total

1.  Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.

Authors:  S Haya; M F López; J A Aznar; J Batlle
Journal:  Haemophilia       Date:  2001-03       Impact factor: 4.287

2.  von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients.

Authors:  A Kallas; T Talpsep
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

3.  Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

Authors:  M Gensana; C Altisent; J A Aznar; P Casaña; F Hernández; J I Jorquera; M Magallón; M Massot; L Puig
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

4.  The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.

Authors:  D M DiMichele; B L Kroner
Journal:  Thromb Haemost       Date:  2002-01       Impact factor: 5.249

5.  Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.

Authors:  J Batlle; M F Lopez; H H Brackmann; S Gaillard; J Goudemand; J Humbert; P De Moerloose; E Maass; C Mauz-Körholz; Y Sultan; N Stieltjes
Journal:  Haemophilia       Date:  1999-11       Impact factor: 4.287

6.  Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.

Authors:  G Mariani; B Kroner
Journal:  Haematologica       Date:  2001-11       Impact factor: 9.941

Review 7.  Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Thromb Haemost       Date:  2010-09-13       Impact factor: 5.249

8.  Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-beta is a significant immunomodulatory component of FVIII.

Authors:  G Hodge; P Han
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

9.  The prevalence of proteolytic antibodies against factor VIII in hemophilia A.

Authors:  Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Namita Misra; Michael P Horn; Sylvie Villard; Anastas Pashov; Natalie Stieltjes; Roseline d'Oiron; Jean-Marie Saint-Remy; Johan Hoebeke; Michel D Kazatchkine; Joseph Reinbolt; Dipika Mohanty; Srini V Kaveri
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

Review 10.  The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Authors:  Günter Auerswald; Torsten Spranger; Hans-Hermann Brackmann
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941
View more
  2 in total

Review 1.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

2.  Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report.

Authors:  Peter Kubisz; Ivana Plamenova; Pavol Holly; Jan Stasko
Journal:  J Med Case Rep       Date:  2012-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.